nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—CYP3A4—bone cancer	0.577	1	CbGaD
Zalcitabine—SLC22A7—Methotrexate—bone cancer	0.0667	0.493	CbGbCtD
Zalcitabine—SLC22A6—Methotrexate—bone cancer	0.0284	0.21	CbGbCtD
Zalcitabine—CYP2C9—Cisplatin—bone cancer	0.0201	0.148	CbGbCtD
Zalcitabine—CYP2D6—Doxorubicin—bone cancer	0.0123	0.0909	CbGbCtD
Zalcitabine—CYP3A4—Doxorubicin—bone cancer	0.00782	0.0578	CbGbCtD
Zalcitabine—DCK—Pyrimidine metabolism—NT5C3A—bone cancer	0.00589	0.102	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00478	0.0833	CbGpPWpGaD
Zalcitabine—CYP3A43—Xenobiotics—CYP3A4—bone cancer	0.00231	0.0402	CbGpPWpGaD
Zalcitabine—DCK—Nucleotide metabolism—NT5C3A—bone cancer	0.00229	0.0399	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—DHFR—bone cancer	0.0022	0.0383	CbGpPWpGaD
Zalcitabine—DCK—Doxorubicin—Epirubicin—bone cancer	0.00217	0.519	CbGdCrCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP4V2—bone cancer	0.00206	0.0358	CbGpPWpGaD
Zalcitabine—DCK—Epirubicin—Doxorubicin—bone cancer	0.00201	0.481	CbGdCrCtD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00193	0.0335	CbGpPWpGaD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00139	0.0242	CbGpPWpGaD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—DHFR—bone cancer	0.00126	0.0219	CbGpPWpGaD
Zalcitabine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000995	0.0173	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000991	0.0172	CbGpPWpGaD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000982	0.0171	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000959	0.0167	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000946	0.0165	CbGpPWpGaD
Zalcitabine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000939	0.0163	CbGpPWpGaD
Zalcitabine—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.00093	0.0162	CbGpPWpGaD
Zalcitabine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000894	0.0156	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000854	0.0149	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000829	0.0144	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000777	0.0135	CbGpPWpGaD
Zalcitabine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.0007	0.0122	CbGpPWpGaD
Zalcitabine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000672	0.0117	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000648	0.0113	CbGpPWpGaD
Zalcitabine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000647	0.0113	CbGpPWpGaD
Zalcitabine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000609	0.0106	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.0006	0.0104	CbGpPWpGaD
Zalcitabine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000571	0.00995	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000551	0.00959	CbGpPWpGaD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000531	0.00924	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—bone cancer	0.000492	0.00857	CbGpPWpGaD
Zalcitabine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000478	0.00832	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000476	0.00828	CbGpPWpGaD
Zalcitabine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000474	0.00825	CbGpPWpGaD
Zalcitabine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000462	0.00803	CbGpPWpGaD
Zalcitabine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00046	0.008	CbGpPWpGaD
Zalcitabine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000456	0.00793	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000448	0.0078	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000426	0.00742	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000423	0.00736	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—CYP3A4—bone cancer	0.000413	0.00719	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP3A4—bone cancer	0.000407	0.00709	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00039	0.00679	CbGpPWpGaD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000386	0.00672	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000382	0.00665	CbGpPWpGaD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000381	0.00663	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—GSTP1—bone cancer	0.000353	0.00615	CbGpPWpGaD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00035	0.00609	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—GSTP1—bone cancer	0.000348	0.00606	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000332	0.00579	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00033	0.00574	CbGpPWpGaD
Zalcitabine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000325	0.00566	CbGpPWpGaD
Zalcitabine—Tachycardia—Cisplatin—bone cancer	0.000318	0.0014	CcSEcCtD
Zalcitabine—Skin disorder—Cisplatin—bone cancer	0.000317	0.0014	CcSEcCtD
Zalcitabine—Hyponatraemia—Doxorubicin—bone cancer	0.000316	0.0014	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000315	0.00139	CcSEcCtD
Zalcitabine—Pain in extremity—Doxorubicin—bone cancer	0.000315	0.00139	CcSEcCtD
Zalcitabine—Osteoarthritis—Doxorubicin—bone cancer	0.000315	0.00139	CcSEcCtD
Zalcitabine—Hyperhidrosis—Cisplatin—bone cancer	0.000315	0.00139	CcSEcCtD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000313	0.00545	CbGpPWpGaD
Zalcitabine—Dry skin—Epirubicin—bone cancer	0.000312	0.00138	CcSEcCtD
Zalcitabine—Eosinophilia—Methotrexate—bone cancer	0.000312	0.00137	CcSEcCtD
Zalcitabine—Abdominal pain upper—Epirubicin—bone cancer	0.000311	0.00137	CcSEcCtD
Zalcitabine—Anorexia—Cisplatin—bone cancer	0.000311	0.00137	CcSEcCtD
Zalcitabine—Affect lability—Doxorubicin—bone cancer	0.00031	0.00137	CcSEcCtD
Zalcitabine—Migraine—Doxorubicin—bone cancer	0.00031	0.00137	CcSEcCtD
Zalcitabine—Hypokalaemia—Epirubicin—bone cancer	0.00031	0.00137	CcSEcCtD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00031	0.0054	CbGpPWpGaD
Zalcitabine—Pancreatitis—Methotrexate—bone cancer	0.000308	0.00136	CcSEcCtD
Zalcitabine—Nasopharyngitis—Epirubicin—bone cancer	0.000305	0.00134	CcSEcCtD
Zalcitabine—Gastritis—Epirubicin—bone cancer	0.000301	0.00133	CcSEcCtD
Zalcitabine—Muscular weakness—Epirubicin—bone cancer	0.0003	0.00133	CcSEcCtD
Zalcitabine—Mood swings—Doxorubicin—bone cancer	0.000299	0.00132	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000297	0.00131	CcSEcCtD
Zalcitabine—Abdominal distension—Epirubicin—bone cancer	0.000296	0.00131	CcSEcCtD
Zalcitabine—Ataxia—Doxorubicin—bone cancer	0.000296	0.00131	CcSEcCtD
Zalcitabine—Blood creatinine increased—Doxorubicin—bone cancer	0.000295	0.0013	CcSEcCtD
Zalcitabine—Dysphagia—Epirubicin—bone cancer	0.000294	0.0013	CcSEcCtD
Zalcitabine—Dysuria—Methotrexate—bone cancer	0.000294	0.0013	CcSEcCtD
Zalcitabine—Neutropenia—Methotrexate—bone cancer	0.000294	0.0013	CcSEcCtD
Zalcitabine—Eosinophilia—Epirubicin—bone cancer	0.000292	0.00129	CcSEcCtD
Zalcitabine—Dyspnoea—Cisplatin—bone cancer	0.000291	0.00128	CcSEcCtD
Zalcitabine—Dry skin—Doxorubicin—bone cancer	0.000289	0.00128	CcSEcCtD
Zalcitabine—Pancreatitis—Epirubicin—bone cancer	0.000289	0.00127	CcSEcCtD
Zalcitabine—Abdominal pain upper—Doxorubicin—bone cancer	0.000288	0.00127	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Methotrexate—bone cancer	0.000287	0.00127	CcSEcCtD
Zalcitabine—Hypokalaemia—Doxorubicin—bone cancer	0.000287	0.00127	CcSEcCtD
Zalcitabine—Decreased appetite—Cisplatin—bone cancer	0.000283	0.00125	CcSEcCtD
Zalcitabine—Nasopharyngitis—Doxorubicin—bone cancer	0.000282	0.00124	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—TP53—bone cancer	0.000281	0.00488	CbGpPWpGaD
Zalcitabine—Depression—Methotrexate—bone cancer	0.00028	0.00123	CcSEcCtD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000279	0.00486	CbGpPWpGaD
Zalcitabine—Gastritis—Doxorubicin—bone cancer	0.000279	0.00123	CcSEcCtD
Zalcitabine—Pain—Cisplatin—bone cancer	0.000279	0.00123	CcSEcCtD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000279	0.00485	CbGpPWpGaD
Zalcitabine—Muscular weakness—Doxorubicin—bone cancer	0.000278	0.00123	CcSEcCtD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000276	0.0048	CbGpPWpGaD
Zalcitabine—Dysuria—Epirubicin—bone cancer	0.000275	0.00122	CcSEcCtD
Zalcitabine—Neutropenia—Epirubicin—bone cancer	0.000275	0.00122	CcSEcCtD
Zalcitabine—Abdominal distension—Doxorubicin—bone cancer	0.000274	0.00121	CcSEcCtD
Zalcitabine—Dysphagia—Doxorubicin—bone cancer	0.000272	0.0012	CcSEcCtD
Zalcitabine—Pollakiuria—Epirubicin—bone cancer	0.000272	0.0012	CcSEcCtD
Zalcitabine—Eosinophilia—Doxorubicin—bone cancer	0.00027	0.00119	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Epirubicin—bone cancer	0.000269	0.00119	CcSEcCtD
Zalcitabine—Feeling abnormal—Cisplatin—bone cancer	0.000269	0.00119	CcSEcCtD
Zalcitabine—Pancreatitis—Doxorubicin—bone cancer	0.000267	0.00118	CcSEcCtD
Zalcitabine—Weight decreased—Epirubicin—bone cancer	0.000266	0.00118	CcSEcCtD
Zalcitabine—Hyperglycaemia—Epirubicin—bone cancer	0.000266	0.00117	CcSEcCtD
Zalcitabine—Epistaxis—Methotrexate—bone cancer	0.000265	0.00117	CcSEcCtD
Zalcitabine—Body temperature increased—Cisplatin—bone cancer	0.000258	0.00114	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Epirubicin—bone cancer	0.000257	0.00114	CcSEcCtD
Zalcitabine—Jaundice—Epirubicin—bone cancer	0.000256	0.00113	CcSEcCtD
Zalcitabine—Neutropenia—Doxorubicin—bone cancer	0.000255	0.00112	CcSEcCtD
Zalcitabine—Dysuria—Doxorubicin—bone cancer	0.000255	0.00112	CcSEcCtD
Zalcitabine—Hepatitis—Methotrexate—bone cancer	0.000252	0.00111	CcSEcCtD
Zalcitabine—Pollakiuria—Doxorubicin—bone cancer	0.000252	0.00111	CcSEcCtD
Zalcitabine—DCK—Metabolism—NDUFA12—bone cancer	0.000251	0.00437	CbGpPWpGaD
Zalcitabine—Pharyngitis—Methotrexate—bone cancer	0.00025	0.0011	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Doxorubicin—bone cancer	0.000249	0.0011	CcSEcCtD
Zalcitabine—Epistaxis—Epirubicin—bone cancer	0.000248	0.00109	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—NDUFA12—bone cancer	0.000248	0.00431	CbGpPWpGaD
Zalcitabine—Weight decreased—Doxorubicin—bone cancer	0.000246	0.00109	CcSEcCtD
Zalcitabine—Sinusitis—Epirubicin—bone cancer	0.000246	0.00109	CcSEcCtD
Zalcitabine—Hyperglycaemia—Doxorubicin—bone cancer	0.000246	0.00108	CcSEcCtD
Zalcitabine—Visual impairment—Methotrexate—bone cancer	0.000243	0.00107	CcSEcCtD
Zalcitabine—Hypersensitivity—Cisplatin—bone cancer	0.00024	0.00106	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000238	0.00105	CcSEcCtD
Zalcitabine—Jaundice—Doxorubicin—bone cancer	0.000237	0.00104	CcSEcCtD
Zalcitabine—Rhinitis—Epirubicin—bone cancer	0.000236	0.00104	CcSEcCtD
Zalcitabine—Hepatitis—Epirubicin—bone cancer	0.000236	0.00104	CcSEcCtD
Zalcitabine—Eye disorder—Methotrexate—bone cancer	0.000235	0.00104	CcSEcCtD
Zalcitabine—Tinnitus—Methotrexate—bone cancer	0.000235	0.00104	CcSEcCtD
Zalcitabine—Asthenia—Cisplatin—bone cancer	0.000234	0.00103	CcSEcCtD
Zalcitabine—Pharyngitis—Epirubicin—bone cancer	0.000234	0.00103	CcSEcCtD
Zalcitabine—Epistaxis—Doxorubicin—bone cancer	0.000229	0.00101	CcSEcCtD
Zalcitabine—Sinusitis—Doxorubicin—bone cancer	0.000228	0.00101	CcSEcCtD
Zalcitabine—Visual impairment—Epirubicin—bone cancer	0.000227	0.001	CcSEcCtD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000226	0.00394	CbGpPWpGaD
Zalcitabine—Chills—Methotrexate—bone cancer	0.000226	0.000997	CcSEcCtD
Zalcitabine—Diarrhoea—Cisplatin—bone cancer	0.000223	0.000984	CcSEcCtD
Zalcitabine—Alopecia—Methotrexate—bone cancer	0.000223	0.000982	CcSEcCtD
Zalcitabine—Eye disorder—Epirubicin—bone cancer	0.00022	0.000972	CcSEcCtD
Zalcitabine—Tinnitus—Epirubicin—bone cancer	0.00022	0.00097	CcSEcCtD
Zalcitabine—Flushing—Epirubicin—bone cancer	0.000219	0.000965	CcSEcCtD
Zalcitabine—Rhinitis—Doxorubicin—bone cancer	0.000219	0.000965	CcSEcCtD
Zalcitabine—Hepatitis—Doxorubicin—bone cancer	0.000218	0.000962	CcSEcCtD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000218	0.00379	CbGpPWpGaD
Zalcitabine—Pharyngitis—Doxorubicin—bone cancer	0.000216	0.000955	CcSEcCtD
Zalcitabine—Dysgeusia—Methotrexate—bone cancer	0.000215	0.000947	CcSEcCtD
Zalcitabine—Back pain—Methotrexate—bone cancer	0.000212	0.000936	CcSEcCtD
Zalcitabine—Chills—Epirubicin—bone cancer	0.000211	0.000933	CcSEcCtD
Zalcitabine—Arrhythmia—Epirubicin—bone cancer	0.000211	0.000929	CcSEcCtD
Zalcitabine—Visual impairment—Doxorubicin—bone cancer	0.00021	0.000927	CcSEcCtD
Zalcitabine—Alopecia—Epirubicin—bone cancer	0.000208	0.000919	CcSEcCtD
Zalcitabine—DCK—Metabolism—NT5C3A—bone cancer	0.000208	0.00362	CbGpPWpGaD
Zalcitabine—Vomiting—Cisplatin—bone cancer	0.000207	0.000915	CcSEcCtD
Zalcitabine—Vision blurred—Methotrexate—bone cancer	0.000207	0.000912	CcSEcCtD
Zalcitabine—Rash—Cisplatin—bone cancer	0.000206	0.000907	CcSEcCtD
Zalcitabine—Dermatitis—Cisplatin—bone cancer	0.000205	0.000906	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—NT5C3A—bone cancer	0.000205	0.00357	CbGpPWpGaD
Zalcitabine—Eye disorder—Doxorubicin—bone cancer	0.000204	0.000899	CcSEcCtD
Zalcitabine—Ill-defined disorder—Methotrexate—bone cancer	0.000203	0.000898	CcSEcCtD
Zalcitabine—Tinnitus—Doxorubicin—bone cancer	0.000203	0.000897	CcSEcCtD
Zalcitabine—Anaemia—Methotrexate—bone cancer	0.000203	0.000894	CcSEcCtD
Zalcitabine—Flushing—Doxorubicin—bone cancer	0.000202	0.000893	CcSEcCtD
Zalcitabine—Flatulence—Epirubicin—bone cancer	0.000202	0.000892	CcSEcCtD
Zalcitabine—Tension—Epirubicin—bone cancer	0.000201	0.000888	CcSEcCtD
Zalcitabine—Dysgeusia—Epirubicin—bone cancer	0.000201	0.000887	CcSEcCtD
Zalcitabine—Nervousness—Epirubicin—bone cancer	0.000199	0.000879	CcSEcCtD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000199	0.00346	CbGpPWpGaD
Zalcitabine—Back pain—Epirubicin—bone cancer	0.000198	0.000876	CcSEcCtD
Zalcitabine—Malaise—Methotrexate—bone cancer	0.000198	0.000872	CcSEcCtD
Zalcitabine—Muscle spasms—Epirubicin—bone cancer	0.000197	0.00087	CcSEcCtD
Zalcitabine—Vertigo—Methotrexate—bone cancer	0.000197	0.000869	CcSEcCtD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000197	0.00343	CbGpPWpGaD
Zalcitabine—Leukopenia—Methotrexate—bone cancer	0.000196	0.000866	CcSEcCtD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000196	0.00341	CbGpPWpGaD
Zalcitabine—Chills—Doxorubicin—bone cancer	0.000196	0.000863	CcSEcCtD
Zalcitabine—Arrhythmia—Doxorubicin—bone cancer	0.000195	0.00086	CcSEcCtD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000194	0.00338	CbGpPWpGaD
Zalcitabine—Vision blurred—Epirubicin—bone cancer	0.000193	0.000853	CcSEcCtD
Zalcitabine—Alopecia—Doxorubicin—bone cancer	0.000193	0.00085	CcSEcCtD
Zalcitabine—Cough—Methotrexate—bone cancer	0.000191	0.000844	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000191	0.00332	CbGpPWpGaD
Zalcitabine—Ill-defined disorder—Epirubicin—bone cancer	0.00019	0.00084	CcSEcCtD
Zalcitabine—Convulsion—Methotrexate—bone cancer	0.00019	0.000838	CcSEcCtD
Zalcitabine—Anaemia—Epirubicin—bone cancer	0.00019	0.000837	CcSEcCtD
Zalcitabine—Agitation—Epirubicin—bone cancer	0.000189	0.000832	CcSEcCtD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000188	0.00327	CbGpPWpGaD
Zalcitabine—Flatulence—Doxorubicin—bone cancer	0.000187	0.000825	CcSEcCtD
Zalcitabine—Arthralgia—Methotrexate—bone cancer	0.000187	0.000824	CcSEcCtD
Zalcitabine—Myalgia—Methotrexate—bone cancer	0.000187	0.000824	CcSEcCtD
Zalcitabine—Tension—Doxorubicin—bone cancer	0.000186	0.000822	CcSEcCtD
Zalcitabine—Dysgeusia—Doxorubicin—bone cancer	0.000186	0.00082	CcSEcCtD
Zalcitabine—Malaise—Epirubicin—bone cancer	0.000185	0.000816	CcSEcCtD
Zalcitabine—Discomfort—Methotrexate—bone cancer	0.000184	0.000814	CcSEcCtD
Zalcitabine—Nervousness—Doxorubicin—bone cancer	0.000184	0.000814	CcSEcCtD
Zalcitabine—Vertigo—Epirubicin—bone cancer	0.000184	0.000813	CcSEcCtD
Zalcitabine—Syncope—Epirubicin—bone cancer	0.000184	0.000812	CcSEcCtD
Zalcitabine—Leukopenia—Epirubicin—bone cancer	0.000184	0.00081	CcSEcCtD
Zalcitabine—Back pain—Doxorubicin—bone cancer	0.000184	0.00081	CcSEcCtD
Zalcitabine—Muscle spasms—Doxorubicin—bone cancer	0.000183	0.000805	CcSEcCtD
Zalcitabine—Palpitations—Epirubicin—bone cancer	0.000181	0.0008	CcSEcCtD
Zalcitabine—Confusional state—Methotrexate—bone cancer	0.00018	0.000796	CcSEcCtD
Zalcitabine—Loss of consciousness—Epirubicin—bone cancer	0.00018	0.000796	CcSEcCtD
Zalcitabine—Cough—Epirubicin—bone cancer	0.000179	0.00079	CcSEcCtD
Zalcitabine—Vision blurred—Doxorubicin—bone cancer	0.000179	0.000789	CcSEcCtD
Zalcitabine—Convulsion—Epirubicin—bone cancer	0.000178	0.000784	CcSEcCtD
Zalcitabine—Infection—Methotrexate—bone cancer	0.000178	0.000784	CcSEcCtD
Zalcitabine—Hypertension—Epirubicin—bone cancer	0.000177	0.000782	CcSEcCtD
Zalcitabine—Ill-defined disorder—Doxorubicin—bone cancer	0.000176	0.000777	CcSEcCtD
Zalcitabine—Anaemia—Doxorubicin—bone cancer	0.000175	0.000774	CcSEcCtD
Zalcitabine—Thrombocytopenia—Methotrexate—bone cancer	0.000175	0.000773	CcSEcCtD
Zalcitabine—Myalgia—Epirubicin—bone cancer	0.000175	0.000771	CcSEcCtD
Zalcitabine—Arthralgia—Epirubicin—bone cancer	0.000175	0.000771	CcSEcCtD
Zalcitabine—Agitation—Doxorubicin—bone cancer	0.000174	0.00077	CcSEcCtD
Zalcitabine—Anxiety—Epirubicin—bone cancer	0.000174	0.000768	CcSEcCtD
Zalcitabine—Skin disorder—Methotrexate—bone cancer	0.000174	0.000767	CcSEcCtD
Zalcitabine—Hyperhidrosis—Methotrexate—bone cancer	0.000173	0.000763	CcSEcCtD
Zalcitabine—Discomfort—Epirubicin—bone cancer	0.000173	0.000762	CcSEcCtD
Zalcitabine—Malaise—Doxorubicin—bone cancer	0.000171	0.000755	CcSEcCtD
Zalcitabine—Dry mouth—Epirubicin—bone cancer	0.000171	0.000754	CcSEcCtD
Zalcitabine—Vertigo—Doxorubicin—bone cancer	0.000171	0.000753	CcSEcCtD
Zalcitabine—Anorexia—Methotrexate—bone cancer	0.000171	0.000753	CcSEcCtD
Zalcitabine—Syncope—Doxorubicin—bone cancer	0.00017	0.000751	CcSEcCtD
Zalcitabine—Leukopenia—Doxorubicin—bone cancer	0.00017	0.00075	CcSEcCtD
Zalcitabine—Confusional state—Epirubicin—bone cancer	0.000169	0.000745	CcSEcCtD
Zalcitabine—Palpitations—Doxorubicin—bone cancer	0.000168	0.00074	CcSEcCtD
Zalcitabine—Oedema—Epirubicin—bone cancer	0.000167	0.000739	CcSEcCtD
Zalcitabine—Loss of consciousness—Doxorubicin—bone cancer	0.000167	0.000736	CcSEcCtD
Zalcitabine—Infection—Epirubicin—bone cancer	0.000166	0.000734	CcSEcCtD
Zalcitabine—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000166	0.00289	CbGpPWpGaD
Zalcitabine—Cough—Doxorubicin—bone cancer	0.000166	0.000731	CcSEcCtD
Zalcitabine—Shock—Epirubicin—bone cancer	0.000165	0.000727	CcSEcCtD
Zalcitabine—Convulsion—Doxorubicin—bone cancer	0.000164	0.000726	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000164	0.00285	CbGpPWpGaD
Zalcitabine—Thrombocytopenia—Epirubicin—bone cancer	0.000164	0.000723	CcSEcCtD
Zalcitabine—Hypertension—Doxorubicin—bone cancer	0.000164	0.000723	CcSEcCtD
Zalcitabine—Tachycardia—Epirubicin—bone cancer	0.000163	0.000721	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000163	0.000719	CcSEcCtD
Zalcitabine—Skin disorder—Epirubicin—bone cancer	0.000163	0.000718	CcSEcCtD
Zalcitabine—Hyperhidrosis—Epirubicin—bone cancer	0.000162	0.000714	CcSEcCtD
Zalcitabine—Insomnia—Methotrexate—bone cancer	0.000162	0.000714	CcSEcCtD
Zalcitabine—Myalgia—Doxorubicin—bone cancer	0.000162	0.000713	CcSEcCtD
Zalcitabine—Arthralgia—Doxorubicin—bone cancer	0.000162	0.000713	CcSEcCtD
Zalcitabine—Anxiety—Doxorubicin—bone cancer	0.000161	0.000711	CcSEcCtD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000161	0.0028	CbGpPWpGaD
Zalcitabine—Discomfort—Doxorubicin—bone cancer	0.00016	0.000705	CcSEcCtD
Zalcitabine—Anorexia—Epirubicin—bone cancer	0.00016	0.000704	CcSEcCtD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00016	0.00278	CbGpPWpGaD
Zalcitabine—Dyspnoea—Methotrexate—bone cancer	0.00016	0.000704	CcSEcCtD
Zalcitabine—Somnolence—Methotrexate—bone cancer	0.000159	0.000702	CcSEcCtD
Zalcitabine—Dry mouth—Doxorubicin—bone cancer	0.000158	0.000698	CcSEcCtD
Zalcitabine—Dyspepsia—Methotrexate—bone cancer	0.000157	0.000695	CcSEcCtD
Zalcitabine—Confusional state—Doxorubicin—bone cancer	0.000156	0.000689	CcSEcCtD
Zalcitabine—Decreased appetite—Methotrexate—bone cancer	0.000156	0.000686	CcSEcCtD
Zalcitabine—Oedema—Doxorubicin—bone cancer	0.000155	0.000684	CcSEcCtD
Zalcitabine—Fatigue—Methotrexate—bone cancer	0.000154	0.000681	CcSEcCtD
Zalcitabine—Infection—Doxorubicin—bone cancer	0.000154	0.000679	CcSEcCtD
Zalcitabine—Pain—Methotrexate—bone cancer	0.000153	0.000675	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000153	0.00266	CbGpPWpGaD
Zalcitabine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000153	0.000673	CcSEcCtD
Zalcitabine—Shock—Doxorubicin—bone cancer	0.000152	0.000673	CcSEcCtD
Zalcitabine—Thrombocytopenia—Doxorubicin—bone cancer	0.000152	0.000669	CcSEcCtD
Zalcitabine—Insomnia—Epirubicin—bone cancer	0.000151	0.000668	CcSEcCtD
Zalcitabine—Tachycardia—Doxorubicin—bone cancer	0.000151	0.000667	CcSEcCtD
Zalcitabine—Skin disorder—Doxorubicin—bone cancer	0.00015	0.000664	CcSEcCtD
Zalcitabine—Hyperhidrosis—Doxorubicin—bone cancer	0.00015	0.000661	CcSEcCtD
Zalcitabine—Dyspnoea—Epirubicin—bone cancer	0.000149	0.000659	CcSEcCtD
Zalcitabine—Somnolence—Epirubicin—bone cancer	0.000149	0.000657	CcSEcCtD
Zalcitabine—Anorexia—Doxorubicin—bone cancer	0.000148	0.000652	CcSEcCtD
Zalcitabine—Feeling abnormal—Methotrexate—bone cancer	0.000147	0.000651	CcSEcCtD
Zalcitabine—Dyspepsia—Epirubicin—bone cancer	0.000147	0.00065	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Methotrexate—bone cancer	0.000146	0.000646	CcSEcCtD
Zalcitabine—Decreased appetite—Epirubicin—bone cancer	0.000146	0.000642	CcSEcCtD
Zalcitabine—Fatigue—Epirubicin—bone cancer	0.000144	0.000637	CcSEcCtD
Zalcitabine—Pain—Epirubicin—bone cancer	0.000143	0.000632	CcSEcCtD
Zalcitabine—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000142	0.00248	CbGpPWpGaD
Zalcitabine—Urticaria—Methotrexate—bone cancer	0.000142	0.000627	CcSEcCtD
Zalcitabine—Abdominal pain—Methotrexate—bone cancer	0.000141	0.000624	CcSEcCtD
Zalcitabine—Body temperature increased—Methotrexate—bone cancer	0.000141	0.000624	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000141	0.000623	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.00014	0.00244	CbGpPWpGaD
Zalcitabine—Insomnia—Doxorubicin—bone cancer	0.00014	0.000618	CcSEcCtD
Zalcitabine—Dyspnoea—Doxorubicin—bone cancer	0.000138	0.00061	CcSEcCtD
Zalcitabine—Feeling abnormal—Epirubicin—bone cancer	0.000138	0.000609	CcSEcCtD
Zalcitabine—Somnolence—Doxorubicin—bone cancer	0.000138	0.000608	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Epirubicin—bone cancer	0.000137	0.000604	CcSEcCtD
Zalcitabine—Dyspepsia—Doxorubicin—bone cancer	0.000136	0.000602	CcSEcCtD
Zalcitabine—Decreased appetite—Doxorubicin—bone cancer	0.000135	0.000594	CcSEcCtD
Zalcitabine—Fatigue—Doxorubicin—bone cancer	0.000134	0.000589	CcSEcCtD
Zalcitabine—Urticaria—Epirubicin—bone cancer	0.000133	0.000587	CcSEcCtD
Zalcitabine—Pain—Doxorubicin—bone cancer	0.000132	0.000585	CcSEcCtD
Zalcitabine—Abdominal pain—Epirubicin—bone cancer	0.000132	0.000584	CcSEcCtD
Zalcitabine—Body temperature increased—Epirubicin—bone cancer	0.000132	0.000584	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000132	0.00229	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Methotrexate—bone cancer	0.000132	0.000582	CcSEcCtD
Zalcitabine—Asthenia—Methotrexate—bone cancer	0.000128	0.000566	CcSEcCtD
Zalcitabine—Feeling abnormal—Doxorubicin—bone cancer	0.000128	0.000563	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000127	0.000559	CcSEcCtD
Zalcitabine—Pruritus—Methotrexate—bone cancer	0.000127	0.000559	CcSEcCtD
Zalcitabine—Hypersensitivity—Epirubicin—bone cancer	0.000123	0.000544	CcSEcCtD
Zalcitabine—Urticaria—Doxorubicin—bone cancer	0.000123	0.000543	CcSEcCtD
Zalcitabine—Abdominal pain—Doxorubicin—bone cancer	0.000122	0.00054	CcSEcCtD
Zalcitabine—Body temperature increased—Doxorubicin—bone cancer	0.000122	0.00054	CcSEcCtD
Zalcitabine—Diarrhoea—Methotrexate—bone cancer	0.000122	0.00054	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.00012	0.00209	CbGpPWpGaD
Zalcitabine—Asthenia—Epirubicin—bone cancer	0.00012	0.00053	CcSEcCtD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000119	0.00206	CbGpPWpGaD
Zalcitabine—Pruritus—Epirubicin—bone cancer	0.000118	0.000523	CcSEcCtD
Zalcitabine—Dizziness—Methotrexate—bone cancer	0.000118	0.000522	CcSEcCtD
Zalcitabine—Diarrhoea—Epirubicin—bone cancer	0.000115	0.000506	CcSEcCtD
Zalcitabine—Hypersensitivity—Doxorubicin—bone cancer	0.000114	0.000504	CcSEcCtD
Zalcitabine—Vomiting—Methotrexate—bone cancer	0.000114	0.000502	CcSEcCtD
Zalcitabine—Rash—Methotrexate—bone cancer	0.000113	0.000498	CcSEcCtD
Zalcitabine—Dermatitis—Methotrexate—bone cancer	0.000113	0.000497	CcSEcCtD
Zalcitabine—Headache—Methotrexate—bone cancer	0.000112	0.000495	CcSEcCtD
Zalcitabine—Asthenia—Doxorubicin—bone cancer	0.000111	0.000491	CcSEcCtD
Zalcitabine—Dizziness—Epirubicin—bone cancer	0.000111	0.000489	CcSEcCtD
Zalcitabine—Pruritus—Doxorubicin—bone cancer	0.00011	0.000484	CcSEcCtD
Zalcitabine—Vomiting—Epirubicin—bone cancer	0.000106	0.00047	CcSEcCtD
Zalcitabine—Diarrhoea—Doxorubicin—bone cancer	0.000106	0.000468	CcSEcCtD
Zalcitabine—Rash—Epirubicin—bone cancer	0.000106	0.000466	CcSEcCtD
Zalcitabine—Dermatitis—Epirubicin—bone cancer	0.000105	0.000465	CcSEcCtD
Zalcitabine—Headache—Epirubicin—bone cancer	0.000105	0.000463	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000103	0.00179	CbGpPWpGaD
Zalcitabine—Dizziness—Doxorubicin—bone cancer	0.000102	0.000452	CcSEcCtD
Zalcitabine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000101	0.00176	CbGpPWpGaD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000101	0.00176	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NDUFA12—bone cancer	9.97e-05	0.00174	CbGpPWpGaD
Zalcitabine—Vomiting—Doxorubicin—bone cancer	9.85e-05	0.000435	CcSEcCtD
Zalcitabine—Rash—Doxorubicin—bone cancer	9.77e-05	0.000431	CcSEcCtD
Zalcitabine—Dermatitis—Doxorubicin—bone cancer	9.76e-05	0.000431	CcSEcCtD
Zalcitabine—Headache—Doxorubicin—bone cancer	9.71e-05	0.000428	CcSEcCtD
Zalcitabine—DCK—Metabolism—ENO2—bone cancer	9.12e-05	0.00159	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—ENO2—bone cancer	8.98e-05	0.00156	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.55e-05	0.00149	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.47e-05	0.00147	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—DHFR—bone cancer	8.46e-05	0.00147	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	8.43e-05	0.00147	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.36e-05	0.00145	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—DHFR—bone cancer	8.33e-05	0.00145	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NT5C3A—bone cancer	8.26e-05	0.00144	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GNA11—bone cancer	7.91e-05	0.00138	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GNA11—bone cancer	7.79e-05	0.00136	CbGpPWpGaD
Zalcitabine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.38e-05	0.00128	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—GSTP1—bone cancer	7.31e-05	0.00127	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.25e-05	0.00126	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	7.21e-05	0.00126	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NDUFA12—bone cancer	7.21e-05	0.00125	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP3A4—bone cancer	7.17e-05	0.00125	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.15e-05	0.00124	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP3A4—bone cancer	7.06e-05	0.00123	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GSTP1—bone cancer	6.13e-05	0.00107	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GSTP1—bone cancer	6.04e-05	0.00105	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NT5C3A—bone cancer	5.97e-05	0.00104	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NDUFA12—bone cancer	5.12e-05	0.000892	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NDUFA12—bone cancer	5.08e-05	0.000884	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.78e-05	0.000832	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.71e-05	0.000821	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.25e-05	0.000739	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NT5C3A—bone cancer	4.21e-05	0.000733	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—ENO2—bone cancer	3.62e-05	0.00063	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—DHFR—bone cancer	3.36e-05	0.000584	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.35e-05	0.000583	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTGS2—bone cancer	3.18e-05	0.000553	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GNA11—bone cancer	3.14e-05	0.000546	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTGS2—bone cancer	3.13e-05	0.000545	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CYP3A4—bone cancer	2.84e-05	0.000495	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.78e-05	0.000483	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—ENO2—bone cancer	2.62e-05	0.000455	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GSTP1—bone cancer	2.43e-05	0.000423	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—DHFR—bone cancer	2.43e-05	0.000422	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GNA11—bone cancer	2.27e-05	0.000395	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.06e-05	0.000358	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—ENO2—bone cancer	1.86e-05	0.000324	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—ENO2—bone cancer	1.84e-05	0.000321	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GSTP1—bone cancer	1.76e-05	0.000306	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—DHFR—bone cancer	1.73e-05	0.0003	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—DHFR—bone cancer	1.71e-05	0.000298	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GNA11—bone cancer	1.61e-05	0.000281	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GNA11—bone cancer	1.6e-05	0.000278	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.46e-05	0.000254	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.45e-05	0.000252	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.44e-05	0.000251	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTGS2—bone cancer	1.26e-05	0.000219	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTP1—bone cancer	1.25e-05	0.000218	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTP1—bone cancer	1.24e-05	0.000216	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—ENO2—bone cancer	1.22e-05	0.000212	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—DHFR—bone cancer	1.13e-05	0.000196	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GNA11—bone cancer	1.05e-05	0.000183	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTGS2—bone cancer	9.11e-06	0.000159	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTP1—bone cancer	8.17e-06	0.000142	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTGS2—bone cancer	6.48e-06	0.000113	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTGS2—bone cancer	6.42e-06	0.000112	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTGS2—bone cancer	4.24e-06	7.37e-05	CbGpPWpGaD
